By Josh Beckerman
Harmony Biosciences shares rose 19% Tuesday as third-quarter net product revenue increased 37% on strong demand for narcolepsy drug Wakix and the company announced a $200 million stock-buyback program.
The stock was recently at $23.49 and is down about 57% this year.
Adjusted…
Read the full article here